CSL.AU CSL Ltd

Healthcare Biotechnology Australian Securities Exchange
200.73 AUD
Close of Nov 1, 2026
88.83 202.85
Market cap
AUD 96.3B
P/E
-
P/B
4.59x
ROE
-17.4%
Dividend yield
2.02%
Fundamental score
1.6/5

Ratios use the latest price and the fiscal year ending Jun 2026.

Is CSL.AU undervalued?

Graham number

The Graham number of CSL Ltd cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

CSL Ltd fundamental analysis

7 of 21 checks passed

ROE 0/2

Low return on equity (-17.4%), below 10%.

ROA 1/1

Return on assets (-7.7%) is above the industry median (-51.4%).

Profit Consistency 0/2

Not profitable for at least 3 consecutive years.

Earnings Growth 5Y 0/1

Earnings per share did not grow over the past 5 years.

Earnings Acceleration 0/1

Not enough positive earnings history to compare last year's growth with the 5-year average.

Earnings Growth vs Industry 0/1

Last year's EPS growth (-186.6%) is below the industry median (-5.3%).

Revenue Growth 1/2

Revenue grew 6.0% a year over the past 3 years.

Short-term Liquidity 1/1

Current assets cover short-term liabilities.

Long-term Liabilities 0/1

Current assets do not cover long-term liabilities.

Debt to Equity 1/2

Moderate debt to equity (73.6%), up to 100%.

Debt Trend 0/1

Debt to equity has risen over the past 5 years.

Cash Runway 2/2

Loss-making but free cash flow is positive.

PE vs Market 0/1

PE is negative or not available.

PE vs Industry 0/1

PE is negative or not available.

PBV 0/1

Price to book (4.6x) is above the industry median (4.4x).

Graham Number 0/1

Graham number needs positive earnings and book value.

PEG 0/1

PEG needs positive PE and positive 5-year earnings growth.

Dividend Yield 0/2

Dividend yield cannot be calculated.

Dividend Stability 2/2

Dividends paid without a cut of more than 10% for 11 years.

Dividend Growth 1/1

Dividends paid grew over the past 5 years.

Payout Ratio 0/1

No dividend, or no profit to pay it from.

Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score

CSL Ltd stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About CSL Ltd

CSL Limited engages in the research, development, manufacture, market, and distribution of biopharmaceutical products and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment manufactures, markets, and distributes plasma products, gene therapies, and recombinants. The CSL Seqirus segment manufactures, mar…

Full company profile